FINWIRES · TerminalLIVE
FINWIRES

Merck's Keytruda, Padcev Combination to Treat Bladder Cancer Receives Positive EU Recommendation; Shares Up Pre-Bell

By

Merck (MRK) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Keytruda, in combination with Padcev, to treat a type of bladder cancer.

The pharmaceutical company said the treatment is preoperative, which then continues after radical cystectomy as supportive treatment for adults with resectable muscle-invasive bladder cancer. The treatment is indicated for patients who are ineligible for cisplatin-containing chemotherapy.

Shares of Merck were up more than 3% pre-bell.

Price: $119.50, Change: $+3.62, Percent Change: +3.12%

Related Articles

Wire

Zoom Communications Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Zoom Communications (ZM) reported fiscal Q1 adjusted diluted earnings late Thursday of $1.55 a share, up from $1.43 a year earlier.Analysts polled by FactSet expected $1.42.Revenue in the three months ended April 30 rose to $1.24 billion from $1.17 billion a year earlier.Analysts surveyed by FactSet expected $1.22 billion.The company expects fiscal Q2 non-GAAP diluted EPS of $1.45 to $1.47 on revenue of $1.265 billion to $1.27 billion. Analysts expect EPS of $1.49 on revenue of $1.266 billion.Zoom expects full-year non-GAAP diluted EPS of $5.96 to $6 on revenue of $5.08 billion to $5.09 billion, up from the prior outlook of EPS of $5.77 to $5.81 on revenue of $5.065 billion to $5.075 billion.Analysts polled by FactSet expect EPS of $5.88 on revenue of $5.075 billion.Zoom shares rose 7% in after-hours trading.

$ZM
Wire

Deckers Outdoor Fiscal Q4 Earnings Fall, Revenue Rises; Sets Fiscal 2027 Guidance

Deckers Outdoor (DECK) reported fiscal Q4 earnings late Thursday of $0.96 per diluted share, down from $1.00 a year earlier.Analysts polled by FactSet expected $0.83.Net sales for the quarter ended March 31 were $1.12 billion, up from $1.02 billion a year earlier.Analysts surveyed by FactSet expected $1.09 billion.The company expects fiscal 2027 earnings of $7.30 to $7.45 per share on net consolidated sales of $5.86 billion to $5.91 billion. Analysts polled by FactSet expect $7.35 and $5.82 billion, respectively.The company said its board has approved an increase of $3.5 billion to the stock repurchase authorization, which brings total outstanding authorization to about $5 billion.

$DECK
Wire

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

Earnings Flash (TTWO) Take-Two Interactive Software Posts Fiscal Q4 Per Share Loss -$0.32, vs. FactSet Est of $-0.57 Loss

$TTWO